KBC, it could turn out that Eversana may decide to roll the dice and convert the debt to equity. At today's SPP, converting, let's say $10Mil debt / $0.35 SPP would net Eversana ~30 Mil RVX shares. If they do, that would send a strong signal indicating that the COVID-19 Phase 2 trial in a hospitalized setting may be showing positive signs, thus the trial being concluded early by design, giving way to Resverlogix's Type C Meeting with FDA for CORAL, Phase 3 High-risk Covid-19 Outpatient Study. 

At the March 22, 2022, "Corporate Overview & COVID Clinical Program Update" podcast, it was mentioned that in the Phase 3 US trial we'll be enrolling patients out of clinical sites which would expedite the program and now as a compromise decision, perhaps pushed by Eversana, are going with the High-risk Covid-19 Outpatient Study.     

Glass half full ... Koo